Ulla Hald Buhl
Chief Operating Officer bei CHOSA ONCOLOGY AB
Profil
Ulla Hald Buhl founded Oncology Venture Sweden AB in 2012, where she worked as Chief Operating Officer & Director.
Ms. Buhl also founded Buhl Krone Holding ApS, where she worked as Chief Executive Officer.
Ms. Buhl also currently works at Chosa Oncology AB, as Chief Operating Officer & Director from 2023.
Ms. Buhl also formerly worked at Cessatech A, as Chairman from 2020 to 2021, Topotarget A, as Director-Investor Relations & Communications, Allarity Therapeutics Europe ApS, as COO, Director & Head-Communication from 2012 to 2019, Oncology Venture US, Inc., as Director from 2016 to 2019, Wntresearch AB, as Chief Clinical Operations from 2010 to 2016, Medical Prognosis Institute A, as Chief Investor Relations & Communications Officer, Liplasome Pharma ApS, as Chief Clinical Operations from 2010 to 2016, and Allarity Therapeutics A, as Chief Operating Officer from 2012 to 2019.
Ms. Buhl received her undergraduate degree from the University of Southern Denmark.
Aktive Positionen von Ulla Hald Buhl
| Unternehmen | Position | Beginn |
|---|---|---|
| CHOSA ONCOLOGY AB | Chief Operating Officer | 01.01.2023 |
| Buhl Krone Holding ApS | Chief Executive Officer | - |
Ehemalige bekannte Positionen von Ulla Hald Buhl
| Unternehmen | Position | Ende |
|---|---|---|
| CESSATECH A/S | Chairman | 01.07.2021 |
Allarity Therapeutics Europe ApS
 Allarity Therapeutics Europe ApS Pharmaceuticals: MajorHealth Technology Allarity Therapeutics Europe ApS operates as a pharmaceutical company that provides oncology products. The firm engages in diagnostics and drug development. The company was founded by Steen Meier Knudsen on August 1, 2012 and is headquartered in Hørsholm, Denmark. | Chief Operating Officer | 01.10.2019 |
Allarity Therapeutics A/S
 Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | Chief Operating Officer | 01.10.2019 |
Oncology Venture US, Inc.
 Oncology Venture US, Inc. Miscellaneous Commercial ServicesCommercial Services Oncology Venture US, Inc. develops therapies for cancer treatment. The company is headquartered in Cambridge, MA. | Director/Board Member | 01.10.2019 |
| WNTRESEARCH AB | Corporate Officer/Principal | 01.01.2016 |
Ausbildung von Ulla Hald Buhl
| University of Southern Denmark | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| WNTRESEARCH AB | Health Technology |
| CESSATECH A/S | Health Technology |
| CHOSA ONCOLOGY AB | Commercial Services |
| Private Unternehmen | 8 |
|---|---|
Topotarget A/S
 Topotarget A/S Pharmaceuticals: MajorHealth Technology Topotarget A/S is a biotechnology company that is engaged in the development and commercialization of novel drugs for the treatment of cancer. Its product belinostat is a novel histone deacetylase inhibitor which is used for cancer patients. The company was founded by Peter Buhl Jensen and Maxwell Sehested in 2000 and is headquartered in Copenhagen, Denmark. | Health Technology |
Medical Prognosis Institute A/S
 Medical Prognosis Institute A/S BiotechnologyHealth Technology Medical Prognosis Institute A/S engages in the research and development of drugs and treatments for cancer and other related illnesses. It operates through the following segments: X Labs, Predict, Ventures, Personal, and Diagnostic business areas. The X Labs business area offers invent, prototype, and prove relevant techniques, scientific methodologies and business models. The Predict business area utilize the method to generate drug and patient response reports. The Ventures business area focuses on business development ventures. The Personal business area engages in developing business to consumer products and services. The Diagnostic business area operates lung chip diagnostics. The company was founded by Steen Knudsen in September 2004 and is headquartered in Horsholm, Denmark. | Health Technology |
Allarity Therapeutics Europe ApS
Allarity Therapeutics Europe ApS Pharmaceuticals: MajorHealth Technology Allarity Therapeutics Europe ApS operates as a pharmaceutical company that provides oncology products. The firm engages in diagnostics and drug development. The company was founded by Steen Meier Knudsen on August 1, 2012 and is headquartered in Hørsholm, Denmark. | Health Technology |
Oncology Venture Sweden AB
 Oncology Venture Sweden AB BiotechnologyHealth Technology Oncology Venture Sweden AB engages in research and development of anti-cancer drugs through its subsidiary Oncology Ventures ApS. It focuses on diagnostics and development of medicinal products for treatment of cancer. The company was founded by Peter Buhl Jensen, Steen Meier Knudsen, Nils Aage Brünner, and Ulla Hald Buhl on June 4, 2015 and is headquartered in Hørsholm, Denmark. | Health Technology |
Liplasome Pharma ApS
 Liplasome Pharma ApS Pharmaceuticals: MajorHealth Technology Liplasome Pharma ApS operates as a biotech company focusing on oncology. It develops drug delivery technologies for anticancer market. The firm's drug delivery platform consists of a lipid based drug delivery system for the intravenous transportation of anticancer drugs and prodrugs. The company was founded in 2002 and is headquartered in Hoersholm, Denmark. | Health Technology |
Oncology Venture US, Inc.
Oncology Venture US, Inc. Miscellaneous Commercial ServicesCommercial Services Oncology Venture US, Inc. develops therapies for cancer treatment. The company is headquartered in Cambridge, MA. | Commercial Services |
Allarity Therapeutics A/S
Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | Health Technology |
| Buhl Krone Holding ApS |
